Research · Sep 3, 2026
[MDT] Medtronic Thesis 2026: Hugo US Approval + Diabetes Recovery Test Operational Rebuild Trajectory
Medtronic FY2025 (Apr 2025) revenue ~$33.5B (+3-5% organic) with adj. operating margin recovering to 24% (from FY2023 trough 22% post supply chain + execution issues). MiniMed 780G hybrid closed-loop insulin pump (US launch FY2024 after multi-year FDA delays) restoring Diabetes segment recovery — segment operating margin recovering toward 16-18% from FY2023 trough 12%. Hugo robotic surgery system commercial in international markets, FDA approval for US pending. Elliott Management activist pressure plus broader investor advocacy for portfolio simplification + Diabetes divestiture/spinoff + capital return acceleration. FY2026 thesis: continued operational excellence + Hugo US approval potential + Diabetes recovery + activist-driven strategic actions; key risks: sustained operational challenges, Hugo competitive disappointment vs Intuitive Surgical da Vinci, Diabetes competitive intensity (Tandem t:slim X2 + Insulet Omnipod 5).